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Inflammation and Atrial Fibrillation
Anthony M. Sideris, MD, Kostas Letsas, MD
A B S T R A C T
There is accumulating evidence pointing to an important association between inflam-
mation and atrial fibrillation (AF). Elevated plasma levels of several markers of the 
inflammatory cascade have been shown to predict future risk of AF. Inflammation 
is likely to represent a novel target for both the treatment and prevention of atrial 
fibrillation.
I N T R O D U C T I O N
Recent advances have raised the hope of effective pharmacological or non-phar-
macological treatments of atrial fibrillation (AF), and of better understanding of the 
pathophysiological mechanisms involved in the initiation and persistence of the ar-
rhythmia. The pathophysiology of AF is complex and multifactorial. The underlying 
etiology is likely different in different patient subpopulations. The development of AF 
leads to many structural and electrical changes contributing to its perpetuation [1]. 
Atrial fibrillation also confers a prothrombotic or hypercoagulable state, which may 
contribute to the risk of thromboembolism [2].
Acute phase response is an innate biological response to a disturbance in homeo-
stasis (infection, inflammation, tissue injury, neoplasm, or immune disturbance). A 
local reaction at the site of injury or infection leads to an activation of cytokines, spe-
cifically interleukin-1 (IL-1), tumor necrosis factor-á (TNF-á), interleukin-6 (IL-6), 
and interferons. Cytokines then trigger systemic responses, which include leukocytosis; 
increases in glucocorticoid production; increases in erythrocyte sedimentation rate, 
fever, activation of complement and clotting cascades and an increase in plasma levels 
of acute phase proteins, C-reactive protein (CRP), serum amyloid A, fibrinogen, and 
other proteins [3].
C-reactive protein is one of the two most abundant acute phase reactants in hu-
mans: levels rapidly increase in the circulation as a result of either trauma or infection. 
Manufactured in the liver and deposited in damaged tissue, CRP is found in high levels 
in inflammatory fluids and in both the intimal layer of the atherosclerotic aortic artery 
and the foam cells within the lesions of atherosclerotic plaque [4,5]. C-reactive protein 
stimulates mononuclear cells to release tissue factor, a protein that is central to the 
initiation of coagulation reactions, complement activation, and the neutralization of 
platelet- activation factor. Together, these reactions promote a thrombotic response [6]. 
C-reactive protein has been traditionally thought of as a bystander marker of vascular 
inflammation, without playing a direct role in the inflammatory process. However, 
recent evidence suggests that CRP may contribute directly to the proinflammatory 
state [7,8]. An increased CRP plasma concentration is strongly associated with the 
CARDIOLOGY UPDATE 2006
2nd Department of Cardiology, 
Evangelismos General Hospital, 
Athens, Greece
KEY WORDS: atrial fibrillation, 
inflammation
HOSPITAL CHRONICLES 2006, SUPPLEMENT: 128–134
Address for correspondence: 
Anthony Sideris, MD
2nd Department of Cardiology
Evagelismos General Hospital
Athens, Greece
E-mail: asideris@hol.gr
LIST OF ABBREVIATIONS:
ACEI: Angiotensin-converting enzyme 
inhibitors
AF: atrial fibrillation
ARB: angiotensin II receptor blockers
CRP: C-reactive protein
IL: interleukin
PUFA: omega-3 polyunsaturated fatty 
acids
RAAS: renin–angiotensin–aldosterone 
system
TNF: tumor necrosis factor
128
HOSPITAL CHRONICLES, SUPPLEMENT 2006 INFLAMMATION AND AF
129
risk of serious cardiovascular events, being the measure of a 
generalized atherosclerotic inflammatory process [9].
I N F L A M M A T O R Y  M A R K E R S
There is accumulating evidence pointing to an important 
association between inflammation and AF. Of all the plasma 
markers of inflammation, CRP has been the most extensively 
investigated in clinical studies. The first observation relating 
inflammation to AF after cardiopulmonary bypass surgery 
was made in 1997 by Bruins et al. They proposed a direct link 
between inflammation and AF by observing an increased fre-
quency of AF after coronary artery bypass surgery. The peak 
incidence of AF occurred on the 2nd-3rd postoperative day, 
coinciding with the maximal elevation of CRP [10].
Inflammatory changes have also been reported in patients 
with non-postoperative AF. Marked inflammatory alterations 
have been observed in atrial specimens obtained from patients 
with isolated persistent AF [11]. Furthermore, Chung, et al 
found that CRP levels were significantly higher in patients with 
paroxysmal and chronic AF than in normal controls, and that 
the level was higher in the chronic AF than in the paroxysmal 
AF group. Thus, they showed that inflammation is involved 
in the onset of AF. However, they stated that whether inflam-
mation is a consequence or a cause of AF remains unknown 
[12]. Some authors suggested the role of inflammation in atrial 
remodelling which promotes the initiation and perpetuation 
of AF [13]. It has been shown that plasma CRP concentration 
is higher in patients with AF, both paroxysmal and persistent, 
compared with the general population [12-14]. An increased 
baseline CRP level is also a risk factor for the development 
of AF during a long-term follow-up period [15]. In one study, 
the combination of microalbuminuria and an elevated hs-CRP 
increased the risk of subsequent AF development by up to 
four-fold [16]. It has also been demonstrated that CRP rep-
resents a robust and significant predictor of early AF relapse 
after succeful cardioversion in patients with AF even after 
adjustment for multiple risk factors, such as hypertension and 
coronary artery disease [14,17,18]. Interestingly, two recent 
studies indicated that CRP relates to the left atrial size and 
AF duration before cardioversion, providing evidence of 
an association between inflammation and atrial structural 
remodelling [19,20].
Another established marker of the inflammatory cascade 
is IL-6. IL-6 is a circulating cytokine produced by monocytes, 
macrophages, lymphocytes and endothelial cells. IL-6 can 
induce a prothrombotic state by increasing expression of fi-
brinogen, tissue factor, factor VIII and von Willebrand factor, 
as well as by activating endothelial cells and increasing platelet 
production [21]. IL-6 is the main hepatic stimulus for CRP 
production [22]. Higher blood levels of IL-6 and fibrinogen 
after coronary artery bypass were observed in patients who de-
veloped AF after surgery. The -174G/C Interleukin-6 promoter 
gene variant appeared to modulate the inflammatory response 
to surgery and to influence the development of postoperative 
AF, suggesting an inflammatory component of postopera-
tive atrial arrhythmias and a genetic predisposition to this 
complication [23]. Similar data have recently been reported 
for patients with non-postoperative AF. Several studies found 
increased levels of IL-6 in patients with AF compared with 
healthy controls [17,19,24-26].
Tumor necrosis factor-á (TNF-á) is a multifunctional 
circulating cytokine derived from endothelial and smooth 
muscle cells as well as macrophages [27,28]. TNF, along with 
interferon-g and IL-1, stimulates IL-6 production by smooth 
muscle cells [29,30]. Sata et al measured TNF-á and other 
indices of inflammation during episodes of paroxysmal AF 
and after the restoration of sinus rhythm in the same patients, 
to clarify the relationship between inflammation and the onset 
of AF. Levels of hs-CRP, IL-6, and TNF after cardioversion 
were significantly higher than those in controls. Furthermore, 
the levels of these indices did not differ significantly even at 
24 hours and 2 weeks after cardioversion. They concluded that 
inflammation is a causative agent of paroxymal AF [25].
A prothrombotic or hypercoagulable state has been 
described in AF, which leads to the high risk of stroke and 
thromboembolism in this condition [1,31-33]. There is an 
apparent link between thrombogenesis and inflammation 
[34-36]. This supports the concept that the observed inflam-
mation in AF increases the risk of thromboembolism as has 
been demonstated for atherosclerotic models. High plasma 
IL-6 levels have been shown to be an independent predictor 
of stroke and the composite end point of stroke and death 
in a prospective study of patients with AF, suggesting that 
inflammation in AF may predict a poor prognosis. Interest-
ingly, trends toward increased risk with high plasma CRP did 
not reach statistical significance [37]. Similarly, Thambidorai 
et al were able to demonstrate in 104 patients with AF that 
clinical and transoesophageal risk factors for stroke were 
greater for patients with elevated CRP compared with those 
with normal levels [38]. This observation is consistent with the 
results reported by Conway et al [26]. A risk score for stroke 
in AF has been correlated with IL-6 [24]. Given the evidence 
so far, the association between markers of inflammation and 
AF suggest that inflammation plays a role in the pathogenesis 
of this arrhythmia.
A N T I - I N F L A M M A T O R Y  I N T E R V E N T I O N S
Drug therapy to prevent AF has traditionally targeted 
atrial electrophysiological mechanisms; however, the proar-
rhythmic effects of such drug therapy have limited its safety. 
An alternative strategy for the prevention of AF would be to 
prevent inflammation.
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G L U C O C O R T I C O I D S
Glucocorticoids are used to treat a wide variety of inflam-
matory diseases. The first observation of a favourable effect 
of corticosteroid treatment on AF was made in 2000 by Yared 
et al [39]. Patients undergoing elective coronary or valvular 
heart surgery were randomized to receive dexamethasone 
or placebo after induction of anesthesia. They found that, 
compared with placebo, patients receiving dexamethasone 
had a lower incidence of new-onset atrial fibrillation during 
the first 3 days postoperatively. However, in another random-
ized, double-blinded, placebo-controlled study, dexametha-
sone failed to decrease the incidence of postoperative atrial 
fibrillation [40]. Dernellis and Panaretou demonstrated that 
the use of low dose glucocorticoids not only improved the 
efficacy of sinus rhythm maintenance postcardioversion but 
was also followed by a fall in CRP levels [14].
S T A T I N S
The use of HMG-CoA reductase inhibitors (statins) in the 
treatment of dyslipidemia has been shown to improve survival 
and significantly reduce the appearance of cardiac events, 
both in primary and secondary prevention [41,42]. Statins also 
have so-called pleiotropic effects, which improve endothelial 
function, reduce inflammation, enhance angiogenesis and vas-
culogenesis, limit oxidative processes, stabilize atherosclerotic 
plaques, and inhibit the thrombogenic response [43,44].
An association between inflammation and AF is undoubt-
edly present. Therefore, therapeutic approaches targeting in-
flammation and oxidative stress may exert favourable effects 
on the risk of AF. Statins have both antiinflammatory and 
antioxidant properties [45,46]. In an animal study, simvastatin 
attenuated AF promotion by atrial tachycardia in dogs, an 
effect not shared by antioxidant vitamins [47]. The available 
evidence tends to prove that statin therapy, which poses anti-
inflammatory properties and reduces CRP levels protects pa-
tients with coronary artery disease from developing AF.This 
effect appeas to be distinct from its cholesterol lowering ability 
[48,49]. Hanna et al analyzed data from Advancent, a large 
multicenter registry of patients with reduced left ventricular 
ejection fraction, to explore the relationship between lipid-
lowering therapy and AF. Lipid-lowering therapy was strongly 
protective against the development of AF. This benefit ap-
peared to be independent of the lipid profile and additive to 
the protective effects of â-blockade and angiotensin convert-
ing enzyme inhibitors (ACEI) or angiotensin receptor blockers 
(ARB) [50]. Similar benefits have been observed in patients 
undergoing coronary artery bypass grafting [51]. C-reactive 
protein lowering with atorvastatin appears to be effective in 
eliminating PAF during daily life in a significant proportion 
of patients [52]. However, in a recent post hoc analysis of a 
large randomized clinical trial, MIRACL study, intensive 
statin treatment did not appear to prevent new AF in the 
16 weeks following acute coronary syndrome [53]. Tveit et al 
also reported that pravastatin did not reduce the recurrence 
rate of AF after electrical cardioversion [54]. Further clinical 
research will determine whether the more widespread use of 
statins will become an important component of the treatment 
of patients with atrial fibrillation.
A N G I O T E N S I N - C O N V E R T I N G  E N Z Y M E  
I N H I B I T O R S  ( A C E I )  A N D  A N G I O T E N S I N  
I I  R E C E P T O R  B L O C K E R S  ( A R B )
Activation of the rennin-angiotensin-aldosterone system 
(RAAS) has been implicated in the pathogenesis of a broad 
spectrum of cardiovascular diseases [55]. Equally, interruption 
of the RAAS by either ACEI and/or ARBs is highly effec-
tive in reducing the known cardiovascular outcomes of these 
diseases [56]. In AF, the RAAS can influence both electrical 
and structural remodelling associated with this arrhythmia 
[55]. There is evidence to date in support of a role for RAAS 
activation as an important factor in the association between 
inflammation and AF. Experimental studies have revealed 
that angiotensin II possesses several proinflammatory prop-
erties, such as the activation of various inflammatory media-
tors (eg, CRP, TNF, IL-6, monocyte chemoattractant protein, 
nuclear factor-kappaB and nuclear factor-alpha), as well as 
stimulating the recruitment and infilitration of neutrophils 
[57,58]. Furthermore, Cardin et al were able to demonstrate 
that increased atrial expression of angiotensin II is linked with 
increased atrial cell death and leukocyte infiltration, again 
supporting a potential link between the RAAS, inflamma-
tion and AF [59]. RAAS blockade elicits anti-iflammatory 
and anti-aggregatory effects in patients with coronary artery 
disease and prevents atherosclerosis and vascular inflamma-
tion [60]. Both ACE-inhibitors and ARBs appear to have 
significant anti-inflammatory actions [61].
Given the potential role of the RAAS in AF, it would be 
rational to suspect that RAAS blockade by ACE inhibitors 
and ARBs may have beneficial effects in AF. Among patients 
enrolled in the SOLVD study of enalapril in left ventricular 
dysfunction, only 5.4% of the patients on enalapril experienced 
AF compared with 24% in the placebo arm. In multivariate 
analysis enalapril was the strongest predictor of reduced AF 
incidence [62]. Healey et al conducted a meta-analysis of the 
available 11 randomized clinical studies on RAAS blockade 
and AF, which included a total of 56,308 patients. They con-
cluded that ACE inhibitors/ARBs reduced the overall risk of 
AF by 28% (P=0.0002). Furthermore, the reduction in AF 
was similarly independent of whether an ACE inhibitor or an 
ARB was the main drug group used (ACE inhibitors: 28%, 
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P=0.01; ARBs: 29%, P=0.00002) [63]. More impressive are 
the data from CHARM and Val-HeFT studies, showing an 
overall 44% relative risk reduction in the development of AF 
among patients with heart failure (P=0.007). The authors also 
noted a clear relationship between worsening heart failure 
(and greater activation of the RAAS system) and greater AF 
prevention [64,65]. Unfortunately, none of the randomized AF 
trials analyzed levels of known inflammatory markers simul-
taneously with the observed beneficial effects in preventing 
either new onset AF or arrhythmia relapse.
P O L Y U N S A T U R A T E D  F A T T Y  A C I D S  
( P U F A )
Evidence from epidemiologic and clinical prevention 
trials suggest that the omega-3 polyunsaturated fatty acids 
(n-3 PUFAs) may have a significant role in protecting against 
death from cardiovascular disease [66-69]. The n-3 PUFAs 
have been shown to exert a range of anti-inflammatory actions 
which include decreased production of arachidonic acid-de-
rived prostaglandins and leukotrienes, decreased production 
of inflammatory cytokines, decreased expression of adhesion 
molecules and decreased expression of degrading proteinases 
that can erode plaque caps [70,71]. As AF has an important 
inflammatory component and n-3 PUFAs are potent anti-
inflammatory agents, recent attention has focused on the 
possible antiarrhythmic effects of PUFA. In cultured rat 
atrial myocytes, n-3 fatty acids reduce induced asynchronous 
contractile activity, suggesting that n-3 fatty acids from fish 
may have antiarrhythmic effects on atrial muscle [72]. Besides 
direct electrophysiological effects, it has been proposed that 
the anti-inflammatory effects of these natural compounds may 
favourably affect atrial remodelling [73]. In a large, prospec-
tive study among elderly adults, greater consumption of tuna 
or other broiled or baked fish was associated with lower risk 
of incident AF. This observed relationship persisted after 
adjustment for a variety of demographic, clinical, lifestyle, 
laboratory, and dietary characteristics, including preced-
ing myocardial infarction and congestive heart failure [74]. 
However, in the Danish Diet, Cancer, and Health study con-
sumption of n-3 fatty acids from fish was not associated with 
a reduction in risk of atrial fibrillation or flutter [75].
A S C O R B I C  A C I D
Antioxidant interventions with vitamin C might have an 
impact against AF-asssociated inflammation. Carnes et al 
were the first to show that an antioxidant intervention with 
vitamin C ameliorates atrial electrical remodeling in experi-
mental animals and significantly reduces the incidence of 
postoperative AF in patients undergoing coronary bypass 
surgery [76]. In a subsequent report examining 46 patients, 
Korantzopoulos et al demonstrated that treatment with vita-
min C reduced the early recurrence of AF after cardioversion 
of persistent AF. In the vitamin C group, CRP levels were 
lower on the seventh day postcardioversion when compared 
with baseline [77].
C O N C L U S I O N
Inflammation plays an important role in the develop-
ment of AF [78-80]. Therefore inflammation may be a new 
therapeutic target in the management of AF. More studies are 
needed to clarify this important issue.
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